Target Price | $15.30 |
Price | $16.30 |
Deviation |
6.13%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Adaptive Biotechnologies Corp 2026 .
The average Adaptive Biotechnologies Corp target price is $15.30.
This is
6.13%
register free of charge
$15.75
3.37%
register free of charge
$11.11
31.84%
register free of charge
|
|
A rating was issued by 14 analysts: 12 Analysts recommend Adaptive Biotechnologies Corp to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Adaptive Biotechnologies Corp stock has an average upside potential 2026 of
6.13%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 178.96 | 237.35 |
5.10% | 32.63% | |
EBITDA Margin | -81.03% | -20.80% |
26.38% | 74.33% | |
Net Margin | -89.12% | -47.48% |
32.63% | 46.72% |
10 Analysts have issued a sales forecast Adaptive Biotechnologies Corp 2025 . The average Adaptive Biotechnologies Corp sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Adaptive Biotechnologies Corp EBITDA forecast 2025. The average Adaptive Biotechnologies Corp EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Adaptive Biotechnologies Corp Analysts have issued a net profit forecast 2025. The average Adaptive Biotechnologies Corp net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.08 | -0.74 |
30.77% | 31.48% | |
P/E | negative | |
EV/Sales | 10.19 |
9 Analysts have issued a Adaptive Biotechnologies Corp forecast for earnings per share. The average Adaptive Biotechnologies Corp EPS is
This results in the following potential growth metrics and future valuations:
Adaptive Biotechnologies Corp...
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 15 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
TD Cowen |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Craig-Hallum |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
Analyst Rating | Date |
---|---|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 15 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 13 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 30 2025 |
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Craig-Hallum:
Locked
➜
Locked
|
Jun 18 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.